Novel approaches in the management of refractory celiac disease

Expert Review of Clinical Immunology

Volumn 4, Issue 2, 2008, Pages 205-219

  Verbeek, Wieke H M ^a   Schreurs, Marco W J ^a   Visser, Otto J ^a   von Blomberg, B Mary E ^a   Al Toma, Abdulbaqi ^b   Mulder, Chris J J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

2 chlorodeoxyadenisine; Aberrant T lymphocyte; Antigen aberrancy; Autologous stem cell transplantation; Celiac disease; Enteropathy associated T cell lymphoma; Flow cytometry; Immunophenotyping; Intestinal T cell; Refractory celiac disease

Indexed keywords

ALEMTUZUMAB; ANTIBODY; AZATHIOPRINE; BUDESONIDE; CARMUSTINE; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; IFOSFAMIDE; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 15; MELPHALAN; METHOTREXATE; PENTOSTATIN; PREDNISONE; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CELIAC DISEASE; CLINICAL TRIAL; CLONAL VARIATION; COLON FISTULA; COMBINATION CHEMOTHERAPY; DUODENUM BIOPSY; FLOW CYTOMETRY; GASTROINTESTINAL HEMORRHAGE; GLUTEN FREE DIET; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOGENETICS; INTESTINE MUCOSA; INTESTINE VILLUS ATROPHY; LYMPHOCYTE SUBPOPULATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NUTRITIONAL STATUS; PATHOGENESIS; PATIENT COMPLIANCE; PRECANCER; PROGNOSIS; REVIEW; SERODIAGNOSIS; SMALL INTESTINE; SMALL INTESTINE PERFORATION; SURVIVAL RATE; SURVIVAL TIME; T CELL DEPLETION; T CELL LYMPHOMA; TARGET CELL; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 46149098335     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.4.2.205     Document Type: Review

References (94)

1. Dube C, Rostom A, Sy R et al. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology 128(4 Suppl. 1), S57-S67 (2005).
2. Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology 120(3), 636-651 (2001).
3. Green PH. The many faces of celiac disease: clinical presentation of celiac disease in the adult population. Gastroenterology 128(4 Suppl. 1), S74-S78 (2005).
4. Wahab PJ, Meijer JW, Mulder CJ. Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. Am. J. Clin. Pathol. 118(3), 459-463 (2002).
5. Daum S, Cellier C, Mulder CJ. Refractory cocliac disease. Best Pract. Res. Clin. Gastroenterol. 19(3), 413-424 (2005).
6. Cellier C, Delabesse E, Helmer C et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 356(9225), 203-208 (2000).
7. Wahab PJ, Meijer JW, Goerres MS et al. Coeliac disease: changing views on glutensensitive enteropathy. Scand. J. Gastroenterol. (236 Suppl.), 60-65 (2002).
8. Biagi F, Corazza GR. Defining gluten refractory enteropathy. Eur. J. Gastroenterol. Hepatol. 13(5), 561-565 (2001).
9. Al-Toma A, Verbeek WH, Hadithi M et al. Survival in refractory coeliac disease and enteropathy associated T cell lymphoma: retrospective evaluation of single centre experience. Gut 57, 1373-1378 (2007).
10. Al-Toma A, Visser OJ, van Roessel HM et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood 109(5), 2243-2249 (2007).
11. When is a coeliac a coeliac? Report of a working group of the United European Gastroenterology Week in Amsterdam. Eur. J. Gastroenterol. Hepatol. (3), 1123-1128 (2001).
12. Patey-Mariaud De SN, Cellier C, Jabri B et al. Distinction between coeliac disease and refractory sprue: a simple immunohistochemical method. Histopathology 37(1), 70-77 (2000).
13. Cellier C, Patey N, Mauvieux L et al. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology 114(3), 471-481 (1998).
14. Carbonnel F, Grollet-Bioul L, Brouet JC et al. Are complicated forms of celiac disease cryptic T-cell lymphomas? Blood 92(10), 3879-3886 (1998).
15. Daum S, Hummel M, Weiss D et al. Refractory sprue syndrome with clonal intraepithelial lymphocytes evolving into overt enteropathy-type intestinal T-cell lymphoma. Digestion 62(), 60-65 (2000).
16. Koning F, Schuppan D, Cerf-Bensussan N et al. Pathomechanisms in celiac disease. Best Pract. Res. Clin. Gastroenterol. 19(3), 373-387 (2005).
17. Maiuri L, Ciacci C, Ricciardelli I et al. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 362(9377), 30-37 (2003).
18. Hue S, Mention JJ, Monteiro RC et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21(3), 367-377 (2004).
19. Meresse B, Chen Z, Ciszewski C et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21(3), 357-366 (2004).
20. Mention JJ, Ben AM, Begue B et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 125(3), 730-745 (2003).
21. Di Sabatino SA, Ciccocioppo R, Cupelli F et al. Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut 55(4), 469-477 (2006).
22. Verbeek WH, Goerres MS, von Blomberg BM et al. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. Clin. Immunol. 126(l), 48-56 (2008).
23. Bhagat G, Naiyer AJ, Shah JG et al. Small intestinal D8TCRγ/ δNKG2A intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac disease. J. Clin. Invest. 1 8(l), 281-293(2008).
24. Sollid LM, Markussen G, Ek J et al. Evidence for a primary association of celiac disease to a particular HLA-DQ α/β heterodimer. J. Exp. Med. 169(l), 345-350 (1989).
25. Polvi A, Arranz E, Fernandez-Arquero M et al. HLA-DQ2-negative celiac disease in Finland and Spain. Hum. Immunol. 59(3), 169-175 (1998).
26. Sollid LM. Molecular basis of celiac disease. Annu. Rev. Immunol. 18, 53-81 (2000).
27. Vader W, Stepniak D, Kooy Y et al. The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc. Natl Acad. Sci. USA 100(21), 12390-12395 (2003).
28. Louka AS, Nilsson S, Olsson M et al. HLA in coeliac disease families: a novel test of risk modification by the 'other' haplotype when at least one DQAI*05-DQB1*02 Haplotype is carried. Tissue Antigens 60(2), 147-154 (2002).
29. Zubillaga P, Vidales MC, Zubillaga I et al. HLA-DQA1 and HLA-DQB1 genetic markers and clinical presentation in celiac disease. J. Pediatr. Gastroenterol. Nutr. 34(5), 548-554 (2002).
30. Congia M, Cucca F, Frau F et al. A gene dosage effect of the DQA1*0501/DQB1*0201 allelic combination influences the clinical heterogeneity of celiac disease. Hum. Immunol. 40(2), 138-142 (1994).
31. Al-Toma A, Goerres MS, Meijer JW et al. Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma. Clin. Gastroenterol. Hepatol. 4(3), 315-319 (2006).
32. Holmes GK, Prior P, Lane MR et al. Malignancy in coeliac disease - effect of a gluten free diet. Gut 30(3), 333-338 (1989).
33. Hadithi M, von Blomberg BM, Crusius JB et al. Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. Ann. Intern. Med. 147(5), 294-302 (2007).
34. Greco L, Romino R, Coto I et al. The first large population based twin study of coelia disease. Gut 50(5), 624-628 (2002).
35. Bevan S, Popat S, Braegger CP et al. Contribution of the MHC region to the familial risk of coeliac disease. J. Med. Genet. 36(9), 687-690 (1999).
36. Monsuur AJ, de Bakker PI, Alizadeh BZ et al. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat. Genet. 37(12), 1341-1344 (2005).
37. Hunt KA, Monsuur AJ, McArdle WL et al. Lack of association of MYO9B genetic variants with coeliac disease in a British cohort. Gut55(7), 969-972 (2006).
38. Amundsen SS, Monsuur AJ, Wapenaar MC et al. Association analysis of MYO9B gene polymorphisms with celiac disease in a Swedish/ Norwegian cohort. Hum. Immunol. 67(4-5), 341-345 (2006).
39. Giordano M, Marano C, Mellai M et al. A family-based study does not confirm the association of MYO9B with celiac disease in the Italian population. Genes Immun. 7(7), 606-608 (2006).
40. Nunez C, Marquez A, Varade J et al. No evidence of association of the MYO9B polymorphisms with celiac disease in the Spanish population. Tissue Antigens 68(6), 489-492 (2006).
41. Sanchez E, Alizadeh BZ, Valdigem G et al. MYO9B gene polymorphisms are associated with autoimmune diseases in Spanish population. Hum. Immunol. 68(7), 610-615 (2007).
42. Koskinen LL, Korponay-Szabo IR, Viiri K et al. Myosin IXB gene region and gluten intolerance: linkage to coeliac disease and a putative dermatitis herpetiformis association. J. Med. Genet. (2007) (Epub ahead of print).
43. Wolters VM, Verbeek WH, Zhernakova A et al. The MYO9B gene is a strong risk factor for developing refractory celiac disease. Clin. Gastroenterol. Hepatol. 5(12), 1399-1405, 1405 (2007).
44. van Heel DA, Franke L, Hunt KA et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat. Genet. 39(7), 827-829 (2007).
45. + phenotypes are increased in coeliac disease. Scand. J. Immunol. 30(6), 665-672 (1989).
46. Savilahti E, Arato A, Verkasalo M. Intestinal γ/δ receptor-bearing T lymphocytes in celiac disease and inflammatory bowel diseases in children. Constant increase in celiac disease. Pediatr. Res. 28(6), 579-581 (1990).
47. + intraepithelial lymphocytes correlate with the grade of villous atrophy in coeliac patients on a long term normal diet. Gut 34(2), 208-214 (1993).
48. Jarvinen TT, Kaukinen K, Laurila K et al. Intraepithelial lymphocytes in celiac disease. Am. J. Gastroenterol. 98(6), 332-1337 (2003).
49. Maki M, Holm K, Collin P et al. Increase in γ/δ T cell receptor bearing lymphocytes in normal small bowel mucosa in latent coeliac disease. Gut 32(11), 1412-1414 (1991).
50. Sturgess R, Kontakou M, Nelufer J et al. γ/δ T-cell receptor expression in the jejunal epithelium of patients with dermatitis herpetiformis and coeliac disease. Clin. Exp. Dermatol. 18(4), 318-321 (1993).
51. Trejdosiewicz LK, Calabrese A, Smart CJ et al. γ/δ T cell receptor-positive cells of the human gastrointestinal mucosa: occurrence and V region gene expression in Heliobacter pylori-associated gastritis, coeliac disease and inflammatory bowel disease. Clin. Exp. Immunol. 84(3), 440-444 (1991).
52. Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology 102(l), 330-354 (1992).
53. Rostami K, Kerckhaert J, Tieniessen R et al. Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice. Am. J. Gastroenterol. 94(4), 888-894 (1999).
54. Rostom A, Dube C, Cranney A et al. The diagnostic accuracy of serologic tests for celiac disease: a systematic review. Gastroenterology 128(4 Suppl. 1), S38-S46 (2005).
55. Collin P, Maki M, Keyrilainen O et al. Selective IgA deficiency and coeliac disease. Scand. J. Gastroenterol. 27(5), 367-371 (1992).
56. Abrams JA, Diamond B, Rotterdam H et al. Seronegative celiac disease: increased prevalence with lesser degrees of villous atrophy. Dig. Dis. Sci. 49(4), 546-550 (2004).
57. Vahedi K, Mascari F, Mary JY et al. Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease. Am. J. Gastroenterol. 98(5), 1079-1087 (2003).
58. Peters JH, Wierdsma NJ, Teerlink T et al. Poor diagnostic accuracy of a single fasting plasma citrulline concentration to assess intestinal energy absorption capacity. Am. J. Gastroenterol. 102(12), 2814-2819 (2007).
59. Isaacson PG, Wright DH, Ralfkiaer E. Enteropathy-type T-cell lymphoma. In: Classification of tumours: pathology and Genetics of tumours of hematopoietic and lymphoid tissues. Jaffe ES, Harris NL, Stein H et al (Eds). IARC Press, Lyon, France 208-209 (2001).
60. Bagdi E, Diss TC, Munson P et al. Mucosal intra-epithelial lymphocytes in enteropathy-associated T-cell lymphoma, ulcerative jejunitis, and refractory celiac disease constitute a neoplastic population. Blood 94(l), 260-264 (1999).
61. Goerres MS, Meijer JW. Wahab PJ et al. Azathioprine and prednisone combination therapy in refractory coeliac disease. Aliment. Pharmacol. Ther. 18(5), 487-494 (2003).
62. Al-Toma A, Goerres MS, Meijer JW et al. Cladribine therapy in refractory celiac disease with aberrant T cells. Clin. Gastroenterol. Hepatol. 4(11), 1322-1327 (2006).
63. Al-Torria A, Verbeek WH, Visser OJ et al. Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. Dig. Liver Dis. 39(7), 634-641 (2007).
64. Daum S, Weiss D, Hummel M et al. Frequency of clonal intraepithelial T lymphocyte proliferations in enteropathy-type intestinal T cell lymphoma, coeliac disease, and refractory sprue. Gut49(6), 804-812 (2001).
65. Yamamoto H, Sekine Y, Sato Y et al. Total enteroscopy with a nonsurgical steerable double-balloon method. Gastrointest. Endosc. 53(2), 216-220 (2001).
66. Hadithi M, Al-Toma A, Oudejans J et al. The value of double-balloon enteroscopy in patients with refractory celiac disease. Am. J. Gastroenterol. 102(5), 987-996 (2007).
67. Ashton-Key M, Diss TC, Pan L et al. Molecular analysis of T-cell clonality in ulcerative jejunitis and enteropathy-associated T-cell lymphoma. Am. J. Pathol. 151(2), 493-498 (1997).
68. Mallant M, Hadithi M, Al-Toma AB et al. Abdominal computed tomography in refractory coeliac disease and enteropathy associated T-cell lymphoma. World J. Gastroenterol. 13(11), 1696-1700 (2007).
69. Tomei E, Diacinti D, Marini M et al. Abdominal CT findings may suggest coeliac disease. Dig. Liver Dis. 37(6), 402-406 (2005).
70. van Weyenberg SJB, Mallant M, Al-Toma A, Jacobs MA, Mulder CJ, Waesberghe JH. Magnetic Resonance Enteroclysis in adult coeliac disease: findings and comparisons between subtypes with different prognosis. OP-G-239 Gut 5 6(Suppl.3), A56 (2007).
71. Hadithi M, Mallant M, Oudejans J et al. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J. Nucl. Med. 47(10), 1622-1627 (2006).
72. Longstreth GF. Successful treatment of refractory sprue with cyclosporine. Ann. Intern. Med. 119(10), 1014-1016 (1993).
73. Vahab PJ, Crusius JB, Meijer JW et al. Cyclosporin in the treatment of adults with refractory coeliac disease - an open pilot study. Aliment. Pharmacol. Ther. 14(6), 767-774 (2000).
74. Mulder CJ, Wahab PJ, Meijer JW et al. A pilot study of recombinant human interleukin-10 in adults with refractory coeliac disease. Eur. J. Gastroenterol. Hepatol. 13(10), 1183-1188 (2001).
75. Maurino E, Niveloni S, Chernavsky A et al. Azathioprine in refractory sprue: results from a prospective, open-label study. Am. J. Gastroenterol. 97(10), 2595-2602 (2002).
76. Daum S, Ipczynski R, Heine B et al. Therapy with budesonide in patients with refractory sprue. Digestion 73(l), 60-68 (2006).
77. Gillett HR, Arnott ID, McIntyre M et al. Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology 122(3), 800-805 (2002).
78. Turner SM, Moorghen M, Probert CS. Refractory coeliac disease: remission with infliximab and immunomodulators. Eur. J. Gastroenterol. Hepatol. 17(6), 667-669 (2005).
79. Goodman GR, Burian C, Koziol JA et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J. Clin. Oncol. 21(5), 891-896 (2003).
80. Dray X, Joly F, Lavergne-Slove A et al. A severe but reversible refractory sprue. Gut 55(8), 1210-1211 (2006).
81. Vivas S, Ruiz de Morales JM, Ramos F et al. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. N. Engl. J. Med. 354(23), 2514-2515 (2006).
82. Verbeek WH, Mulder CJ, Zweegman S. Alemtuzumab for refractory celiac disease. N. Engl. J. Med. 355(13), 1396-1397 (2006).
83. Dearden CE, Matures E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATHAH-1H. Blood 98(6), 1721-1726 (2001).
84. Dearden CE, Matutes E. Alemtuzumab in T-cell lymphoproliferative disorders. Best Pract. Res. Clin. Haematol. 19(4), 795-810 (2006).
85. Catassi C, Fabiani E, Corrao G et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA 287(11), 1413-1419 (2002).
86. Catassi C, Bearzi I, Holmes GK. Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology 128(4 Suppl. 1), S79-S86 (2005).
87. Egan LJ, Walsh SV, Stevens FM et al. Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era. J. Clin. Gastroenterol. 21(2), 123-129 (1995).
88. Daum S, Ullrich R, Heise W et al. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma. J. Clin. Oncol. 21(14), 2740-2746 (2003).
89. Bishton MJ, Haynes AP. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. Br. J. Haematol. 136(l), 111-113 (2007).
90. van Besien KW, Mehra RC, Giralt SA et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am. J. Med. 100(3), 299-307 (1996).
91. Vitolo U, Cortellazzo S, Liberati AM et al. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. J. Clin. Oncol. 15(2), 491-498 (1997).
92. Hosing C, Saliba RM, McLaughlin P et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann. Oncol. 14(5), 737-744 (2003).
93. Doocey RT Toze CL, Connors JM et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br. J. Haematol. 131(2), 223-230. (2005).
94. Gallamini A, Zaja F, Patti C et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linformi) prospective multicenter trial. Blood 110(7), 2316-2323 (2007).